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Introduction
Current methods of treatment for various ocular ailments in-
clude both oral medications and topical eye drops. There are 
significant downsides to both. Orals are often not the first line of 
treatment both because, they take a circuitous route to the eye 
and cause many more negative systemic side effects (Kim, et al., 
2014). Next, in the case of eye drops, there are multiple barriers 
to overcome. First, much of the dispensed eye drop is inhibited 
by pre-corneal factors which include nasolacrimal drainage, tear-
ing, and blinking. These factors significantly lower the bioavailabil-
ity of the medication. Research indicates that only a fraction of 
the precious medication, a mere one percent to seven percent, 
reaches its required destination, thereby reducing the drug’s ef-
fectiveness (Schultz and Mint, 2002). Furthermore, the drops are 
often administered by the patient, and sometimes are required 
multiple times a day. This commonly leasds to low patient com-
pliance, and doses are frequently forgotten or skipped purposely 
(Ciolino et al., 2011). Given the above, there exists an impetus to 
develop alternate methods of delivering ocular medications, thus 
enabling effective treatment. Researchers are currently working 
on developing a contact lens that will also dispense nanoparticles 
of medication directly into the eye while correcting refractive 
error. In patients who don’t have refractive error, the contact 
lenses can simply be worn for the purpose of delivering the 
needed medication into their eyes. The use of contact lenses for 
ocular drug delivery can solve many of the issues associated with 
eye drops. First, the space created by the lens with the cornea 
has limited tear mixing, and potentially a greater amount of con-
tact time between the drug and the cornea.
This causes greater bioavailability. Additionally, there is an 
added benefit of eliminating the need for multiple doses a day, 
which will increase the amount of patient compliance. Under 
ideal kinetics, the drug will release in a time dependent man-
ner, extending the therapeutic effects of one dose (Phan et al., 
2014). Research with a drug dispensing contact lens (DDCL), is 
currently underway for a number of ocular conditions. In this 
work specifically, a DDCL for the diseases of glaucoma, fungal 
keratitis, and hay fever are discussed.
Glaucoma
Glaucoma, a group of conditions that damages the eye’s 
optic nerve, usually results from increased intraocular pres-
sure (IOP) which can result in vision loss and blindness. The 
two main forms are open-angle glaucoma and angle-closure 
glaucoma. Both forms, involve clogging of the eye’s drainage 
canals, leading to elevated ocular pressures and subsequent 
nerve damage. In open-angle glaucoma this leads to a gradual 
increase in IOP because, the angle between the iris and cornea 
is wide and open. In angle-closure glaucoma there is a sudden 
increase in IOP because, the angle between the iris and cornea 
is either very narrow or closed. Current methods of treatment 
include surgery, oral medications, and eye drops, depending on 
the classification and extent of the disease. When surgery is 
warranted however, it usually does not resolve the increased 
IOP completely and generally a regimen of eye drops are pre-
scribed as well post operatively. Additionally, surgery can cause 
negative side effects including, cataract formation, inflamma-
tion, ocular infections, corneal issues, and low IOP. Negative 
side effects caused by oral medications can include irritation, 
stinging, redness, blurred vision, itchiness, low blood pressure, 
fatigue, shortness of breath, headaches, dry mouth, frequent 
urination, upset stomach, and memory problems, depending 
on the class of drug prescribed. In general, topical eye drops 
are the first line of treatment. However, due to the issues 
posited above, a contact lens that can dispense anti-glaucoma 
drugs is currently being developed.
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Research for Anti-Glaucoma Drug Dispensing 
Contact Lens
Joseph B. Ciolino, MD, at the Massachusetts Eye and Ear, con-
ducted an in vivo study on the effectiveness of a Latanoprost-
dispensing contact lens for female monkeys with induced 
glaucoma. Latanoprost is currently on the market as a topical 
anti-glaucoma eye drop. It belongs to a class of anti-glaucoma 
medications knows as prostaglandin analogues, which work to 
lower the IOP by increasing uveoscleral flow (although more re-
cently research suggests that it may occur through a trabecular 
pathway) and it is prescribed for cases of open-angle glaucoma 
(Lindén and Alm, 1999, Winkler and Fautsch, 2013). In Ciolino’s 
research, a thin latanoprost-polymer film was introduced into 
a methafilcon hydrogel contact lens. Both a low-dose contact 
lens (CL), and a high-dose CL were synthesized. The intraocular 
pressure of the glaucomatous monkeys was monitored after a 
period of the following cases:
1. Treatment with Latanoprost eye drops
2. Treatment with CL-low
3. Treatment with CL-high
4. No treatment
The results demonstrated that the latanoprost eye drops suc-
ceeded in reducing IOP approximately 5 mmHg, the CL-lo by 
about 6.5 mmHg, and CL-hi by about 11 mmHg. 
Evidently, “Sustained delivery of latanoprost by contact lenses is 
at least as effective as delivery with daily latanoprost ophthal-
mic solution. More research is needed to determine the opti-
mal continuous-release dose that would be well tolerated and 
maximally effective. Contact lens drug delivery may become an 
option for the treatment of glaucoma and a platform for ocular 
drug delivery (Ciolino et al., 2016)”
Additional anti-glaucoma contact lenses that are currently being 
researched, synthesized, and patented are those that contain 
timolol maleate or brimonidine tartrate within a polymeric hy-
drogel. Timolol maleate belongs to a class of anti-glaucoma drugs 
known as beta-adrenergic blockers and brimonidine tartrate is 
an alpha agonist. Both are prescribed for cases of open-angle 
glaucoma. Specifically, in the case of beta blockers, systemic side 
effects can be pretty severe such as, cardiac arrhythmias, bron-
chospasm, and stroke and is therefore prescribed based on a 
patient’s complete medical history. The aim of the study was 
to develop contact lenses that maintain normal hydration and 
comfort, and will dispense lower doses of drug for extended 
periods of time. This will lead to increased patient compliance, 
decreased negative side effects, and efficacious treatment 
(Schultz and Mint, 2002). 
Etafilcon contact lenses (hydrogels) were washed in a saline 
solution and briefly dried. Then they were immersed in either a 
dilute solution of brimonidine tartrate (0.02%), or a dilute solu-
tion of timolol maleate (0.05%). (Topical ophthalmic solutions of 
the above drugs are commercially available as 0.2% solutions for 
brimonidine, 0.25% for timolol, and 0.5% for timolol ophthalmic 
gel forming solution). The lenses were subsequently tested on 
multiple patients as a replacement for their current regimens of 
eye drops. Instead of the patient administering their daily eye 
drop, he wore the contact lens for 30 minutes each day. In all 
cases, this method allowed for IOP to remain below the nec-
essary value of 20 mmHg, with no evidence of ocular toxicity.  
An additional study was conducted on glaucomatous beagle 
dogs. NIGHT & DAY™ silicone hydrogel contact lenses were 
immersed in timolol and phosphate buffered saline solution. 
Then, one lens was inserted into one of the dog’s eyes, while 
the other eye served as the control, and no lens was inserted. 
The lenses with similar dosing to timolol eye drops led to an 
IOP reduction of about 5 mmHg (which is slightly greater than 
the IOP reduction resulting from timolol eye drops). However, 
lenses with a third drug loading as the eye drops led to a similar 
reduction in intraocular pressure, suggesting increased bioavail-
ability. Finally, the eye without the contact lens remained unaf-
fected by its proximal lens, which suggests reduction in systemic 
absorption of the drug released by the lens (Peng et al., 2012).
Fungal Keratitis
Fungal keratitis is an infection of the cornea (the clear, round 
dome covering the eye’s iris and pupil) which causes pain, re-
duced vision, light sensitivity, and tearing or discharge from the 
eye. Resulting from infection from contact lens use, or from 
injury to the eye, fungal keratitis usually develops very quickly, 
and if left untreated, can cause blindness (Boyd, 2015). Fungal 
keratitis is also prevalent in tropical and subtropical climates 
(Ciolino et al., 2011).
Current treatment options for fungal keratitis vary depending 
on the severity of the condition. Topical eye drops are often 
the first line of treatment (Ciolino et al., 2011). Once again the 
above drawbacks to eye drops are present:
“The failures of topical antimycotic treatments may be 
related to the limitations of eye drops as a form of drug 
delivery. Eye drops generate a transiently high concen-
tration on application followed by a short period of ef-
fective therapeutic concentration and then a prolonged 
period of underdose. Furthermore, each drop is diluted 
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and washed away by reflex tearing and dispersed by 
blinking. As a consequence, only 1% to 7% of drug in a 
drop is absorbed in the eye. The cornea absorbs only 
a fraction of this dose, in part due to the tissue’s short 
contact time with the topical drops (Ciolino et al., 
2011).”
Currently there is only one drug available on the market, na-
tamycin, as a topical ophthalmic antifungal. However, this drug 
specifically is shown to have poor corneal penetration and is 
mainly effective with superficial corneal infections caused by 
Fusarium species (Singh, 2015). Depending on the severity and 
identity of the disease, often subconjunctival injections of an 
antifungal agent are prescribed and the dosage times are not 
infrequent, (twice every hour for the first 24 hours, then once 
every hour for the next 24 hours etc). “Successful antifungal 
therapy for fungal keratitis requires frequent drug administra-
tion for prolonged periods (ie, at least 12 weeks) (Singh, 2015).” 
Sometimes antifungals in an oral form are prescribed. However, 
15 to 27 percent of patients with fungal keratitis require surgical 
intervention (Boyd, 2015). Even after surgery, a course of topical 
drops is often prescribed as well. Finally, surgery is not effective 
in all cases, and a patient may be rendered significantly visually 
impaired (Singh, 2015).
Research for an Anti-Fungal Contact Lens
The ineffectiveness of the topical regiment arises from low 
penetrance of the drug to the corneal epithelium as well as 
inadequate contact time between drug and tissue. Additionally, 
low patient compliance is common due to the frequency with 
which the drug needs to be administered. A contact lens that 
dispenses antifungal particles could resolve all these issues. A 
prototype antifungal contact lens (Ciolino et al., 2011) was syn-
thesized using the following method: 
Econazole, an antifungal drug, was added to a film of poly (lac-
tic-co-glycolic) acid (PLGA). PLGA is desirable because of its 
biocompatibility and biodegradability, and its effectiveness at 
controlling drug release kinetics. Various film sizes were syn-
thesized and all were encapsulated into polyhydroxymethacry-
late (pHEMA), a common contact lens material. Contact lenses 
were synthesized with different concentrations of econazole. 
A control lens was created as well which contained the PLGA 
film inside the pHEMA hydrogel without the econazole. The 
contact lenses were tested against the fungus C. albicans, a 
common agent of fungal keratitis. First the lenses were placed 
directly onto a rich medium, a culture plate containing 1 mL of 
the Candida suspension. After a number of cycles of incubation 
and refreshing the medium, the culture was diluted, incubated, 
and counted for viable colonies. This was done to determine 
the effect of the contact lenses in direct contact with the fungi. 
The lenses were also tested for their drug-releasing capabilities. 
The testing was conducted by immersing the lenses in a yeast 
nitrogen base medium and incubated. Then they were immersed 
in fresh medium every 24 hours. The yeast nitrogen base drug 
release medium was collected at different intervals, and diluted 
with new medium containing C. albicans. Once again after a pe-
riod of dilution and incubation, the suspension was plated and 
counted for viable colonies. 
The results showed that both methods were capable of killing 
100% of fungi for extended intervals. The release medium which 
contained contact lenses with 16 mg of econazole (PLGA-16) 
killed 100% of fungi for 21 days! The mediums from contact 
lenses, containing lower concentrations of econazole, killed fun-
gus for shorter amounts of time. In the cases where the contact 
lenses came directly in contact with the fungal suspension, 100% 
of fungi were killed for 8 to 10 days (with PLGA-16). Studies 
show that C. albicans is more difficult to kill than Fusarium 
species. Therefore if Candida was killed by econazole, Fusarium 
should be as well (Ciolino et al., 2011). (Currently econazole is 
not FDA approved for ophthalmic use, although many ophthal-
mologists would prefer to treat fungal infections with some-
thing other than Natamycin, currently the only available drug). 
Contact lenses that could elute the drug natamycin have also 
been synthesized (Phan et al., 2013). The study focused specifi-
cally on manipulating various contact lens materials. Hydrogels 
were composed of: 
1. 100 % pHEMA, 
2. 85% pHEMA and 15% [Tris(trimethylsiloxy)silyl]-propyl 
methacrylate (TRIS)
3. 75% pHEMA and 25% TRIS 
4. N,N-dimethylacrylamide (DMAA), 
5. 85% DMAA and 15% TRIS
6. 75% DMAA and 25% TRIS 
The lenses were monitored by their uptake and release of two 
forms of natamycin. The first form was Natamycin dissolved in 
deionized water, and the second form was Natamycin encap-
sulated within poly(D,L-lactide)-dextran nanoparticles. Results 
indicated that the optimal materials to use were those contain-
ing DMAA. Furthermore, all gels had a greater uptake with the 
nanoparticles of natamycin versus natamycin alone. Finally, the 
release of natamycin within nanoparticles was greater than the 
natamycin alone. Also, the first hour of release was noteworthy. 
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The lenses with regular natamycin released 28-82% within the 
first hour. In the nanoparticle lenses this was reduced to 21-54% 
(Phan et al., 2013). 
Hay Fever and Allergic Conjunctivitis
“Spring allergies are triggered as trees start blooming and bil-
lions of pollen grains are released into the air, causing suscep-
tible individuals to develop allergic rhinitis… In these patients, 
the pollen causes degranulation of mast cells, which contain 
inflammatory mediators, ie, histamine and other allergy-causing 
chemicals. This process is clinically represented by sneezing; red, 
tearing eyes; postnasal drip; sinus headaches; feelings of sinus 
fullness; and itchy, scratchy throat (Medscape, 2016).”
As the conjunctiva of the eye is a mucosal membrane, it too is 
subjected to the inflammatory responses of allergic rhinitis. Per 
the CDC (Center for Disease Control and Prevention), approx-
imately 19 million adults and another 6 million children suffer 
from hay fever in the U.S. alone. For the ocular symptoms of rhi-
nitis, also known as allergic conjunctivitis, eye drops containing 
anti-histamines and/or mast cell stabilizers can be prescribed or 
recommended. Another class of treatments are corticosteroids 
and glucocorticoids, which also work to reduce the allergic 
reactions which affect the eye and relieve the negative symp-
toms. These can be prescribed as an ophthalmic suspension for 
topical use. Once again due to inhibitive pre-corneal factors, an 
alternate drug delivery mechanism is currently being researched 
in the form of a drug dispensing contact lens. 
Research for DDCLs for Allergic Conjunctivitis
The Kingston University London conducted an in vitro experi-
ment to synthesize a contact lens that could dispense nanopar-
ticles of a synthetic glucocorticoid, prednisolone, into the eyes 
of patients with allergic conjunctivitis. (Currently prednisolone 
is on the market as prednisolone acetate ophthalmic suspension 
for topical use.) The main purpose of the experiment was to 
consider the effects of the encapsulated drug on the contact 
lenses’ functionality and safety as well as the drug’s bioavailabil-
ity (ElShaer et al., 2016). 
Prednisolone nanoparticles (PNP) were synthesized using an 
emulsion-solvent evaporation method. The experiment was de-
signed to maximize three key nanoparticle features: small parti-
cle size (increased surface area/bioavailability), highest encapsu-
lation efficiency, and maximum surface charge (no coagulation 
of particles; increases stability). To obtain the smallest particle 
size, four variables were manipulated: PLGA (poly-lactic-co-gly-
colic acid), PVA (polyvinyl alcohol), API (amount of prednisolone 
used), and homogenization time. Through optimization of these 
components a particle size of about 295 nm was obtained. To 
form the contact lens molds, HEMA (2-hydroxymethacrylate), 
MAA (methacrylic acid) and a small amount of EGDMA (eth-
ylene glycol dimethacrylate) were mixed together along with 
the PNPs. These four hydrogel materials were allowed to polym-
erize thermally for 4 hours at 80°C in molds of polypropylene. 
The in vitro drug release pattern of the contact lens with 0.4 
grams of PNP was observed to be a two-phase process: an ini-
tial burst, followed by a period of slower release. The lens was 
placed in a release medium of phosphate buffered saline for 24 
hours. 10.8% of drug was released in that time. The slow release 
of the drug can be due to the need for the drug to get past its 
nanoparticle barrier and through the contact lens as well. One 
of the issues with eye drops is that all of the drugs are released 
within a few hours. Nanoparticles of medication embedded in 
contact lenses can provide a longer lasting therapeutic regimen 
(ElShaer et al., 2016). 
Method of Drug Release from Contact Lens
Although some studies for drug-eluting contact lenses pre-soak 
the contact lenses in drug, to allow for eventual diffusion into 
the eye, to achieve a more controlled method of release, other 
methods are being researched. The human tear film contains an 
enzyme called lysozyme. In a study on anti-glaucoma contact 
lenses, timolol maleate was encapsulated in nanodiamond (ND) 
particles. The NDs were coated in both polyethyleneimine (PEI) 
and chitosan. Chitosan is an enzyme-cleavable polysaccharide 
and PEI enables a more effective cleavage. The drug release of 
these impregnated lenses was monitored in vitro. In the absence 
of lysozyme, no release of timolol maleate was detected. In the 
presence of lysozyme the lens released 9.41 micrograms in 24 
hours (Kim et al., 2014).
Addition of Drug to Contact Lens Material and 
Subsequent Hydration and Oxygen Permeability
This feature was monitored in the prednisolone study cited 
above. Contact lenses lacking the PNPs had an average hy-
dration of about 36%. Lenses containing a smaller volume 
of drug nanoparticles (0.2 g) had a decreased hydration 
by about 31%, whereas the lenses with a higher volume of 
PNPs (0.4 g) had a further reduction in hydration to about 
30.5%. 
Surface wettability determines comfort of the lens, and was 
measured as well. A good surface wettability is identified by a 
contact angle less than 90 °C. Unmodified lenses have a con-
tact angle of 85 °C. The prednisolone encapsulated lenses had 
further reduced angles which should increase ocular comfort 
(ElShaer et al., 2016). Similarly, contact lenses containing nano-
diamond particles of timolol maleate demonstrated acceptable 
hydration values (Kim et al., 2014).  
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Transparency/light Transmission Capability of 
Drug-Impregnated Lens
Ideally a contact lens should have a light transmittance of 
above 90%, so vision is unobstructed. The control contact 
lenses (lacking PNP) in the prednisolone study had a high 
transparency of 94.5%. The lenses containing 0.2 grams and 
0.4 grams of PNP had a reduced transparency of 86.23% and 
83.1% respectively. However, this amount contributes to low 
or no opacity, and as long as the correct amount of nanopar-
ticle is added to the lens, vision should not be compromised 
(ElShaer et al., 2016). Similarly, addition of nanodiamond par-
ticles of timolol maleate to a pHEMA lens did not cause any 
discernable changes to the lens’ optical clarity. The lens with 
a higher concentration of NDs maintained a transmittance of 
84.5% (Kim et al., 2014).
Dimensions/measurements of Drug-Eluting 
Contact Lenses Compared to Commercially 
Available Lenses
In the study done on antifungal contact lenses, when syn-
thesizing the econazole-laden lenses, parameters of an 8.05 
base curve and a 15.5 mm diameter were measured, which 
are consistent with commercially available lenses (Ciolino et 
al., 2011).
Preservation of Contact Lens through 
Lyophilization (to prevent drug elution/
degradation) Effect on Lens Capability
Depending on the method used to impregnate the lenses with 
drug, there exists a risk of the drug eluting out of the lens during 
storage. In order to combat this, anti-fungal contact lenses were 
lyophilized, a preservation process involving the freeze drying of 
a substance and subsequent removal of water by a vacuum caus-
ing the water to go from an ice state directly to a gaseous one. 
The fungicidal activity of the lyophilized lens was then assessed 
and found to be intact, although the duration of its effectiveness 
was reduced by 1 to 2 days (Ciolino et al., 2011).
Risk Factors and Drawbacks Associated with a DDCL
Although there is a lot of potential is this innovative drug deliv-
ery system, several potential downsides should be noted. There 
are many consumers who do not wear contact lenses because 
they find them uncomfortable or haven’t found the proper fit. 
Others do not wear contact lenses because they have no re-
fractive error and would thus need a special fitting session just 
to wear a short-term lens. Additionally, glaucoma often affects 
the geriatric population. Individuals of this population could also 
have difficulty inserting and removing the lenses, however this 
issue could be aided by an eye-care professional. These factors 
could potentially minimize the market for such lenses. Another 
problematic feature involves the drug-eluting property of the 
lenses. Once removed by the patient any remaining drug may 
continue to diffuse out. In the case of anti-fungal drugs, this 
could have an effect on the development of resistant strains 
while in the case of other drugs this may simply pose as a hazard 
for children. (It should be noted though that with lenses con-
trolled by lysozyme presence this undesired drug-elution may 
be minimized).
Conclusion and Further Applications
Contact lenses for the treatment of glaucoma, fungal keratitis, 
and allergic conjunctivitis have been synthesized and demon-
strate much potential in effective treatment. However, the lens-
es are far from having a clinical relevance. Much more animal 
and human testing is required prior to the necessary FDA-type 
approvals. Although in this paper glaucoma, fungal keratitis, and 
allergic conjunctivitis were discussed, research is also under-
way for additional ocular conditions such as, chronic dry eye 
and bacterial infections (Legett, 2009), (ElShaer et al., 2016). 
Additionally, the studies are working on embedding various drug 
nanoparticles into lenses without obstructing optical transpar-
ency. Potentially, instead of drugs, various ocular-necessary vita-
mins and supplements can serve as the embedded nanoparticle. 
As salt is iodized to promote proper thyroid function, perhaps 
macular degeneration could be prevented by infusing contact 
lenses with nanoparticles of lutein and zeaxanthin, two nutrients 
vital to a healthy macula.
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